BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Intrexon Corporation 

108 T.W. Alexander Drive
PO Box 14088
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: n/a Fax: n/a


Founded in 1998, Intrexon Corporation is a privately held biotechnology company focused on the industrial engineering of synthetic biology. Intrexon is deploying its extensive capabilities to rapidly design and produce novel and enhanced biological products and processes across multiple industry sectors, including: human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company’s advanced bioindustrial engineering platform enables Better DNA™ technology by combining breakthroughs in DNA control systems with corresponding advancements in modular transgene design, assembly, and optimization to enable unprecedented control over the function and output of living cells.

Our mission is to redefine the biotechnology development process by engineering complex multigenic biological and cellular systems at unprecedented scale, dramatically reducing the time, cost, and risks associated with synthetic biology. With an extensive and expanding patent portfolio, Intrexon is working with key channel partners throughout our commercial divisions to utilize the industrial engineering of synthetic biology in developing new products and processes, which will alleviate shortages of essential nutrients, bring better medicines to more people, and generate renewable fuels and other resources. Our Better DNA™ technology provides the foundation to industrialize the development of high-performing biological products and enable many new possibilities across broad industries.

Intrexon’s commercial and core technology divisions are located within the country’s major biotechnology hotbeds. In California, San Francisco is the primary site of the Protein Production and Industrial Products Divisions, with our Cell Engineering Unit nearby in San Diego. Intrexon’s expansive Germantown, Maryland facility is centrally located within the Mid-Atlantic biotech region and is currently home to our Human Therapeutics and Animal Science Divisions, as well as our Molecular Engineering Unit. Corporate headquarters, as well as the UltraVector Technology Division are both located in Blacksburg, Virginia. Finally, the southern states host a second site for our Protein Production Division in Charleston, South Carolina, in addition to our Agricultural Biotech Division in Research Triangle Park, North Carolina.

We are always seeking those who share our passion for excellence, hard work, creativity, and moving beyond the limitations of traditional biotech. ?With Intrexon you will have an exceptional opportunity to join the forefront of the bioindustrial revolution and contribute directly to the future of synthetic biology applications and products.

Please visit for further information on our company.

 Key Statistics

Ownership: Private

Web Site: Intrexon Corporation


 Company News
Intrexon Corporation To Announce Fourth Quarter And Full Year 2014 Financial Results On Monday, March 2, 2015 2/23/2015 7:45:09 AM
Intrexon Corporation Prices Public Offering Of Common Stock 1/22/2015 8:10:46 AM
Intrexon Corporation Announces Proposed Public Offering Of Common Stock 1/21/2015 7:55:49 AM
MD Anderson Cancer Center to Earn $100 Million From Intrexon Corporation and ZIOPHARM Oncology, Inc. (ZIOP.OB) for Immunotherapy Game-changer 1/14/2015 7:04:31 AM
ZIOPHARM Oncology, Inc. (ZIOP.OB) And Intrexon Corporation Present Clinical And Preclinical Data From Immuno-Oncology Programs At Intrexon Corporation Tumor Immunology And Immunotherapy Meeting 12/4/2014 4:22:42 PM
Intrexon Corporation Announces Third Quarter 2014 Financial Results 11/14/2014 7:33:23 AM
Study Demonstrates Automated Laser-Based Cell Manipulation With Intrexon Corporation's Proprietary LEAP® System 11/7/2014 7:10:16 AM
Intrexon Corporation To Announce Third Quarter 2014 Results And Host Conference Call On November 13th 11/6/2014 9:06:51 AM
Intrexon Corporation To Present At Jefferies and Co. 2014 Global Industrials Conference 8/4/2014 8:57:45 AM
Intrexon Corporation's Industrial Products Division Achieves Bioconversion Of Methane To Farnesene 6/30/2014 8:48:52 AM